BenevolentAI Results Presentation Deck
Cash flows focused upon drug and platform
development
Normalised¹ operating loss
Depreciation & amortisation
Foreign exchange
Other employee-related SBP expense
Cash flows from changes in working capital
Cash expended from underlying operating activities
Opening cash, cash equivalents and short-term deposits
Closing cash, cash equivalents and short-term deposits
1) Excludes exceptional costs related to the Business
Combination
31 December
2022
£'000
(94,598)
3,058
BenevolentAl Proprietary
(3,141)
29,935
(13,094)
(77,840)
40,553
130,182
£1.7m property-related leases.
£3.2m gain from EUR holdings; £0.3m
gain from USD holdings; £0.4m charge
from operational.
Non-Transaction-related equity awards
removed from the P&L (no cash impact)
Largely driven by increase in R&D tax
credit receivable (£4.0m), as well as
decrease in SBP employer-related tax
provision (£6.2m).
Year end cash position of £130.2m at the
top end of our stated guidance.
Benevolent 12View entire presentation